
Human Protease and Use of Such Protease for Pharmaceutical Applications and for Reducing the Allergenicity of Non-Human Proteins David A. Estell Docket No. GC532-C1 Sheet 1 of 13



Human Protease and Use of Such Protease for Pharmaceutical Applications and for Reducing the Allergenicity of Non-Human Proteins David A. Estell Docket No. GC532-C1 Sheet 2 of 13

:	100 Se	Met ATG	SS As	Asp GAT	∌్ర	Val GTA
	AC E	ACG T	gg gg CgC	. 3 8 3 3 3	दह	Ly AAG
-107 Met GTG	AG Sé	Ser AGC	Val GTA	∌ §	· 돎 있	Lea TA
AGA	₹ 8	ATG	IAT TAT	6.4 GT	C C C C C C C C C C C C C C C C C C C	GAT B
<u>G</u> ATA	를 알 크	₽ Per ¥S	₹₹	T¥C TAC	Ala GCT	8 2 2
RBS GAGAG	85 65 65	ම දු වි	를 유 그 등	Ala GCT	85	Æ M
4) † ttggttattctgcaaatgaaaaaag <u>gagaga</u> taaaga	Met	₹₹	∌్ కే	val GTC	8 SS	Ser TCT
. AAA	ACG	a E	Lys AAG	Ser	₹\$ &	Ser TCT
AATGA	ag E	99 99	우 등 장	<u>ه</u> 200	lle ATT	AST GAT
IGCA	% 90 ATC	Val	val GTG	Asp GAC	≎ కై రై	lle ATC
ATTC	五色	· -	k ₹	Lys AA	Ser TCA	GGT GGT
)	SCG GCG	PRO Tyr lle TAT: AT	099 099	Lys AA	Val GTA	Ser AGC
CIATA (4)	⊒ E	Lys AA	29 89	Leu TTG	දු ල	Asp GAC
CTGT	Ala	5-73 Lys AAG	Lys A&A	Ger GAA	T¥ TAC	Ile ATC
ATAAT	를 E	<u> </u>	∌	Łys A&A	SCT 25	S A S
CAGA	္က ပ	100 100 100 100 100 100 100 100 100 10	Ser TCT	, cal	Val GTG	GCG GCG
NTACA	PRE Le Le	ASG AGC	lle ATT	Ata GCT MAT	य ह	Val GTA
ATTA	AGT	శ్ర నై	Val GTC	કે કુ દ	CAG CAG	₹
TACA	ATC 470	R ₂ S	& & & & & & & & & & & & & & & & & & &	. 8 €	- 8 S	Val GTT
TACTA	5 5	§ 8	Ly MA	A AC	- £2	Asn
TCCA	Val GTA	₽ 5	Lys	Lev TTA	\$	- Se - 1
ATTAĪ	Lys AA	88 800	Lys	ACA ACA	동 전	g g
P	r _s	CAG G	Ala GCT	Ata GCT	\$ 8	ACT.
<u>IĄ</u> CTA	090 090	8 & 8 8 & 8	Aa GCC	વ્યું સુ	val GTA	Z¥ Z¥C
6670	AGA	ं ह	Ser AGC	Ala GCT	총장	2 & &
-	8	174	249	324	38	474

FIG._1B-1

Human Protease and Use of Such Protease for Pharmaceutical Applications and for Reducing the Allergenicity of Non-Human Proteins David A. Estell Docket No. GC532-C1 Sheet 3 of 13


						_	
Ala COC	ં જે ફ	Met	Ala GCA	G y GGT	er CCT	<u>6</u>	ACT P
Val GTT	Val	ASI AAT	GT Sa	84	₹	Asn	Asn
CAC	Ala GCT	Asn	Ala GCC	TAC	Val GTA	TY TAC	ACA
ACT A	TAC TAC	ෂ් දි	Es BAS	န ်စ	Ser	₽ 33 33 33	म् १९८
€. 66.	8 3 5	lle ATC	55 PS ST ST	Val GTG	8 % 5		240 Asn 5 AAC
CAC	12 & 1	Ala GCG	Val GTT	돌철	₹ 1	TAC	₽ 200 300
Ser TCT	SG As SE	1 թ 166	SS As	Ser	15 15 15	R &	His CAC
Asn	AGC AGC	Gľu GAG	Ata 606	Se TCA	S Aa GCA	Asn AAC	Lys AAG
Asp Asn AAC	£ స్ట్ర	ile ATC	k5 A	Ser AGC	Arg	€ 65 €	Ser TCT
60 Asp GAC	Ala GCG	110 GGA	₹	නි <u>ඉ</u>	₽ ₽	25 CCT	3 E
CA Gi	Val GTT	Asa	Ala	지 Ser 100	ASC	Les CT CT	Leu lle TTG ATT
Phe TTC	29 2 5	lle ATT	Ala GCT	Ser Thr ACT	Ser	ACG	T TG
Asn CCT	TIA E	lle ATC	Ser TCT	<u>چ</u> وور	Ser AGC		AB GCT GCT
Pro Asn AAT	val GTA	1ր 166	GGT GGT	GP GAA	SA CS		AB GCT
ACA	80 Gly GGT	Ser	138 161	Asn AAC	88 kg CT 2		230 AB
<u>a</u> .69	lle ATC	Tyr TAC	25 25 15	Ģ GGT	Aa GCT	12 g	6 € €
Ser TCT	<u> </u>	₽ \$	ල් ල්	SCC CCC	29 29 20		OCC Value
Pro CCT	Asn	ე დე	დ გე	₽ Ş	Val GTA		ST ST
Val GTT	Asn	چ ت	35 35 26	8 8 606	₽ 5		S GG
S0 Met ATG	3 E	5€ 5€7	Ser	55 Val	ATT E		2 000
Ser AGC	Ala GCT	Ata GAC GAC	Met ATG	val GTC	val GTC		Ser A TCT
Ala GCC	. ₽ 000	As SCT	AC AS	val GTA	15. 15.		Ala GCA
y GG ∕	STT C	G√ GGT	a H	val GTC	5 5 7	Asp	
20 2 j	¥ÇA ₹	CIC CIC	Val GTT	. ≽ 8	14 14C		
Ala GCA	2 2 3 3	Val	120 Asp GAC	Ser TCC	동자		4
549	28	669	12.	849		8	1074

Human Protease and Use of Such Protease for Pharmaceutical Applications and for Reducing the Allergenicity of Non-Human Proteins David A. Estell Docket No. GC532-C1 Sheet 4 of 13

250 GIN GIN Val Arg Ser Ser Leu Glu Asn Thr Thr Thr Lys Leu Gly Asp Ser Phe Tyr Tyr Gly Lys Gly Leu IIe Asn 1149 CAA GTC CGC AGC AGT TTA GAA AAC ACC ACT ACA AAA CTT GGT GAT TCT TTC TAC TAT GGA AAA GGG CTG ATC AAC GIN AIA AIA AIA GIN OC TERM
CAG GCG GCA GCT CAG TAA AACATAAAAAAACGGCCTTGGCCCCGCCGGTTTTTATTTTTCTTCCTCCGCATGTTCAATCCGCTCC 270 Val 1224 GTA

1316 ATAATCGACGGATGGCTCCCTCTGAAAATTTTAACGAGAAACGGCGGGTTGACCCGGCTCAGTCCCGTAACGGCCAAGTCCTGAAACGTCTCAATCGCCG 1416 CTTCCCGGTTTCCGGTCAGCTCAATGCCGTAACGGTCGGCGGTTTTCCTGATACCGGGAGACGGCATTCGTAATCGGATC

-1G. 1B - 3



Human Protease and Use of Such Protease for Pharmaceutical Applications and for Reducing the Allergenicity of Non-Human Proteins David A. Estell Docket No. GC532-C1 Sheet 5 of 13

CONSERVED RESIDUES IN SUBTILISINS FROM
BACILLUS AMYLOLIQUEFACIENS

B	AC	ILL	US	A	MY.	LOI	_/(_	UE	FA	SIE	NS	j							
1 A	Q	s	V	P	•	G	•		1	0.	•	A	P	A	•	н	•	•	20 G
2:	1 T	G	s		v	ĸ	v	A	3 (V	0	D	•	G	•	•	•	•	H	40 P
4: D	1 L	•		•	G	G	À	s	5	o V	P	•	•	•	•	•	•	Q	60 D
6:	N L	•	н	G	T	н	v	A	7 (G	T	•	A	A	L		N	s	İ	80 G
81 V	L L	G	v	A	P	s	A	•	9 (L	y Y	A	v _.	ĸ	v	L	G	A		G G
10 S)1 G	•		s	•	L	•		L1(G		E	W	A	•	N	•	•		120
12 V	1	N		s	L	G	•	P	ເສັດ ຮ		s	•	•		•		A	•	140
14	1		•		G	v	•	v	15(V	A	A		G	N	•	G	•		160
16	1	•	•.	•	•	Y	P		.70	Y	•	•	•	•	A	v	G		180
18 D	1		N		•	A	s	F	.90 S			G		•	L	D	•		200 A
20 P	1 G	v	•	•	Q	s	T	. 2	10 P) G		•;	Y	•,	•	•	N		220 T
22 S	1 M	A		P	н	v	A		3 C A		A	L				ĸ			240
24 W	1			Q		R	•	. 2	50 L		N	T			•	L	G	.,	260
26 •	1							2	70)									

FIG._2

Human Protease and Use of Such Protease for Pharmaceutical Applications and for Reducing the Allergenicity of Non-Human Proteins David A. Estell Docket No. GC532-C1 Sheet 6 of 13

			•
д д д д	0000	2001	0000
***	ннын	XXXX	ស ស ស ប
0 0 0 *	8 8 1 8 8	2200	F S Z A
SSAF	zzzz	ZZZZ	0,000
8898	ZZQZ	A to H Z	ស្លាលល
нынн	ㅋㅋㅋㅋ	нныю	* * * *
0000	**	AAAA	0000
SSHF	**	3333	***
9999	> H > H	医瓦瓦瓦瓦	**
мн ныы	_ 6666	Бннны	9 K K K K
30 0 0 0 0	20000	1 1 1 1 1 1 1 1 1	4 4 4 4 5
RARA	***	2 Z W O	>>>>
>>>>	>>>>	нньк	P > > H
KKKK	###	нннн	> H > >
>>>>	***	\$ \$ 0 0	0000
2 2 2 U	0000	សសសស	$\alpha \alpha \alpha \alpha$
ស ឋ 🕁 ស		4444	4040
0000	0000	999	* * * #
FFK	ZOZZ	0000	**
24440	ွူ အပ္ပပ	O	4 0
<u> , , , , , , , , , , , , , , , , , , ,</u>	99999	00000	HAAAX
000 %	aara	O Fr St St	
SYS	京学 * 正	4004	4>44
HEGH	9 9 Z S	טבטט	4 F Q Q
よななな	B K K K	аааа.	KKK E
AAKA	BBA*	>>>>	ななばち
4404	医医尿尿	KKKK	4 4 4 E
RARA	ស ស ស ស	>>>>	4 H H A
KKKQ	₽₽ ₩	AAAA	លលលល
оннн>	0 > > > >	4444 0	6000 00
HOOUR	贝其부부萨	o u u u u	4 B F B B
លលកល	ស ស ស ស	លលល់ស	₽₽ ₩₽
≽ннн	**	4474	ធ ធ ធ ធ
0000	9999	លលលល	0000
**	0000	ыыны	4444
ддда	4 % > %	4044	8888
>>>>	>>> H	>>>>	***
ស ស 🗗 ស	KZZZ	6 6 6 6	ZZZZ
40000	^는 그그그그	н ынын	HHH4
104444 4444	<u>4</u> 0000	80 > > >	4445

COMPARISON OF SUBTILISIN SEQUENCES FROM:
B. amyloliquefaciens
B. subtilis
B. licheniformis
B. lentus

FIG._3A

Human Protease and Use of Such Protease for Pharmaceutical Applications and for Reducing the Allergenicity of Non-Human Proteins David A. Estell Docket No. GC532-C1 Sheet 7 of 13

				!	
				FIG. 3A	38
	MAKK	MENO		ု ဗ	ું છું :
	M M M P	рене			
	> > > H	HHHN			
	DDMD	KKKK	•		~
	コロロロ	8 8 8 G			(
	医医鼠区	なななれ	aaam		<i>IG.</i>
	A A SO PO	ннн>	AAAH		2
	9999	ㅋㅋㅋㅋ	***		
	> < > >	***	***		
0	8 8 8 8 C	9 A A A A	5 a a m m		
H	លលលល	84444	*		
	म म्याय	9999	ZZZZ		
	លលលល	**	нннь		
	***	>>>>	4444		
	我我我我	H H H H	0000		
	OOZZ	рре	KKK 0	•	
	ZZGZ	SHSH	0000		
	SSS	AAAA	4444	\mathbf{m}	
	8 8 8 9	zzzz	211五五五	3	
2	DZDD	20 20 20 20	0 FFFZ	1	
1	>>>	4444	4 8 8 8 E	G	
	***	9999	DMSS	ř	
	0000	ZZZZ	0000		
	>>>>	化作业表	보보보보		
	**	· AAH0	以下 1000		
	нння	0044	e e e e		
	> 4 > 4	在在在 在	HAAA	•	
	ខ្លួ	***	EEE	•	
	PARA	N O N O	2002		
9	A AAA	9 Q Q E Q	о Бий ак		
-	KKKK	4 4 4 4 5	22 4 4 4 4 5		
	DAAA	ままでは	50 真真耳		
	ддде	4444	SEDS		
	エエエエ	ស្លស្ស	联联联联		
	0000	aaka ,	>>>H		
	>> H H	. HH>>	aaaa		
	H H H +	0 0 C Z	F & 0 >		
	សស 🗷 🛊	> > < >	ZZAZ	•	
5	4 H H W	201 201 201 201 201 201 201 201 201 201	4 4 4 4 4 4 8 8 8		
	* 00 00 00 +	77 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3	ZEZEZ Z		





FIG. 4



Human Protease and Use of Such Protease for Pharmaceutical Applications and for Reducing the Allergenicity of Non-Human Proteins David A. Estell Docket No. GC532-C1 Sheet 10 of 13

MKLVNIWLLLLVVLLCGKKHLGDRLEKKSFEKAPCPGCSHLTLKVEFSSTVVEYEYIVAFNGYFT AKARNSFISSALKSSEVDNWRIIPRNNPSSDYPSDFEVIQIKEKQKAGLLTLEDHPNIKRVTPQR KVFRSLKYAESDPTVPCNETRWSQKWQSSRPLRRASLSLGSGFWHATGRHSSRRLLRAIPRQVAQ TLQADVLWQMGYTGANVRVAVFDTGLSEKHPHFKNVKERTNWTNERTLDDGLGHGTFVAGVIASM RECQGFAPDAELHIFRVFTNNQVSYTSWFLDAFNYAILKKIDVLNLSIGGPDFMDHPFVDKVWEL TANNVIMVSAIGNDGPLYGTLNNPADQMDVIGVGGIDFEDNIARFSSRGMTTWELPGGYGRMKPD IVTYGAGVRGSGVKGGCRALSGTSVASPVVAGAVTLLVSTVQKRELVNPASMKQALIASARRLPG VNMFEQGHGKLDLLRAYQILNSYKPQASLSPSYIDLTECPYMWPYCSQPIYYGGMPTVVNVTILN GMGVTGRIVDKPDWQPYLPQNGDNIEVAFSYSSVLWPWSGYLAISISVTKKAASWEGIAQGHVMI TVASPAETESKNGAEQTSTVKLPIKVKIIPTPPRSKRVLWDQYHNLRYPPGYFPRDNLRMKNDPL DWNGDHIHTNFRDMYQHLRSMGYFVEVLGAPFTCFDASQYGTLLMVDSEEEYFPEEIAKLRRDVD NGLSLVIFSDWYNTSVMRKVKFYDENTRQWWMPDTGGANIPALNELLSVWNMGFSDGLYEGEFTL ANHDMYYASGCSIAKFPEDGVVITQTFKDQGLEVLKQETAVVENVPILGLYQIPAEGGGRIVLYG DSNCLDDSHRQKDCFWLLDALLQYTSYGVTPPSLSHSGNRQRPPSGAGSVTPERMEGNHLHRYSK VLEAHLGDPKPRPLPACPRLSWÄKPQPLNETAPSNLWKHQKLLSIDLDKVVLPNFRSNRPQVRPL SPGESGAWDIPGGIMPGRYNQEVGQTIPVFAFLGAMVVLAFFVVQINKAKSRPKRRKPRVKRPQL MQQVHPPKTPSV

FIG. 6

Human Protease and Use of Such Protease for Pharmaceutical Applications and for Reducing the Allergenicity of Non-Human Proteins David A. Estell Docket No. GC532-C1 Sheet 11 of 13

		•			•
1	A12	IKDFHVYFRESRDAG	49	E12	SATSRGVLVVAASGN
2	A11	LEQAVNSATSRGVLV	50	E11	SRGVLVVAASGNSGA
3		AQSVPWGISRVQAPA	51	E10	VLVVAASGNSGAGS I
	A10	VPWGISRVQAPAAHN	52	E9	VAASGNSGAGSISYP
4	Α9	*	53	E8	SGNSGAGSISYPARY
5	A8	GISRVQAPAAHNRGL			
6	Α7	RVQAPAAHNRGLTGS	54	E7	SGAGSISYPARYANA
7	A6	APAAHNRGLTGSGVK	55	E6	GSISYPARYANAMAV
8	A5	AHNRGLTGSGVKVAV	56	E5	SYPAR <u>YANAMAVGA</u> T
9.	A4	RGLTGSGVKVAVLDT	57	E4	ARYANAMAYGATDQN
10	A3 -	TGSGVKVAVLDTGIS	58	E3 .	ANAMAVGATDQNNNR
11		GVKVAVLDTGISTHP	59	E2	MAVGATDQNNNRASF
12	A2	VAVLDTGISTHPDLN	60	ĒĪ	GATDONNNRASFSQY
13	A1	LDTGISTHPDLNIRG	61	F12	DONNNRASFSQYGAG
	B12	GISTHPDLNIRGGAS	62	F11	NNRASFSQYGAGLDI
14.	B11		63		ASFSQYGAGLDIVAP
15	B10	THPDLNIRGGASFVP		F10	
16.	B9	DLNIRGGASFVPGEP	64	F9	SQYGAGLDIVAPGVN
17	B8	IRGGASFVPGEPSTQ	65	F8	GAGLDIVAPGVNVQS
18	B7	GASFVPGEPSTQDGN	66	F7	LDIVAPGVNVQSTYP
19.	В6	FVPGEPSTQDGNGHG	67	F6	VAPGVNVQSTYPGST
20	B5	GEPSTQDGNGHGTHV	68	F5	GVNVQSTYPGSTYAS
21	B4	STQDGNGHGTHVAGT	69	F4	VQSTYPGSTYASLNG
22	B3	DGNGHGTHVAGTIAA	70	F3	TYPGSTYASLNGTSM
23	B2	GHGTHVAGTIAALNN	71	F2	GSTYASLNGTSMATP
24	B1	THVAGTIAALNNSIG	72	FĪ	YASLNGTSMATPHVA
25		AGTIAALNNSIGVLG	73	G12	LNGTSMATPHVAGAA
26	C12	IAALNNSIGVLGVAP	74	G11	TSMATPHVAGAAALV
27	C11	LNNSIGVLGVAPSAE	75	G10	ATPHVAGAAALVKQK
28	C10	SIGVLGVAPSAELYA	76	G9	HVAGAAALVKQKNPS
29	Ç9	VLGVAPSAELYAVKV	77	G8	GAAALVKOKNPSWSN
30	C8	VAPSAELYAVKVLGA	78	G7	ALVKOKNPSWSNVQI
	C7	SAELYAVKVLGASGS	79	G6	KOKNPSWSNVQIRNH
31,	C6	•	80		NPSWSNYQIRNHLKN
32	C5	LYAVKVLGASGSGSV	. 81	G5	WSNVQIRNHLKNTAT
33	C4	VKVLGASGSGSVSSI	82	G4	
34	C3	LGASGSGSVSSIAQG		G3	VQIRNHLKNTATSLG
35	C2	SGSGSVSSIAQGLEW	83	G2	RNHLKNTATSLGSTN
36	C1	GSVSSIAQGLEWAGN	84	G1	LKNTATSLGSTNLYG
37	D12	SSIAQGLEWAGNNGM	. 85	H12	TATSLGSTNLYGSGL
38	D11	AQGLEWAGNNGMHVA	· 86	H11	SLGSTNLYGSGLVNA
39	D10	LEWAGNNGMHVANLS	87	H10	STNLYGSGLVNAEAA
40	D9	AGNNGMHVANLSLGS	88	Н9	NLYGSGLVNAEAATR
41	D8	NGMHVANLSLGSPSP			
42	D7	HVANLSLGSPSPSAT			
43	D6	NLSLGSPSPSATLEQ			
44	D5	LGSPSPSATLEQAVN			
45		PSPSATLEQAVNSAT	•		·
46	D4	SATLEQAVNSATSRG			
47	D3	LEQAVNSATSRGVLV		-	•
48	D2	AVNSATSRGVLVVAA			
40	D1				·

Human Protease and Use of Such Protease for Pharmaceutical Applications and for Reducing the Allergenicity of Non-Human Proteins David A. Estell Docket No. GC532-C1 Sheet 12 of 13

_		IKDFHVYFRESRDAG	49	E12	KKIDVLNLSIGGPDF
1	A12		50	E11	DVLNLSIGGPDFMDH
2	A11	DAELHI FRVFTNNQV	51	E10	NLSIGGPDFMDHPFV
3	A10	PLRRASLSLGSGFWH	52	E9	IGGPDFMDHPFVDKV
4	A9	RASLSLGSGFWHATG	53	E8 ·	PDFMDHPFVDKVWEL
5	A8	LSLGSGFWHATGRHS	54	E7	MDHPFVDKVWELTAN
6	A7	GSGFWHATGRHSSRR		Ē6	PFVDKVWELTANNVI
7	A6	FWHATGRHSSRRLLR	55 56	E5	DKVWELTANNVIMVS
8	A5	ATGRHSSRRLLRAIP	· 56	E4	WELTANNVIMVSAIG
9	A4	RHSSRRLLRAIPRQV	57 50	E3	TANNVIMVSAIGNDG
10	A3	SRRLLRAIPRQVAQT	58	E2	NVIMVSAIGNDGPLY
11 ,	A2	LLRAIPRQVAQTLQA	59	E1	MVSAIGNDGPLYGTJ
12	A1	AIPROVAQTLQADVL	60	F12	AIGNDGPLYGTLNNP
13	B12	RQVAQTLQADVLWQM	61		NDGPLYGTLNNPADQ
14	B11	AQTLQADVLWQMGYT	62	F11	PLYGTLNNPADQMDV
15	B10	LQADVLWQMGYTGAN	63	F10	GTLNNPADQMDVIĞV
16	В9	DVLWQMGYTGANVRV	64	F9	
17	B8	WQMGYTGANVRVAVF	65	F8 F7	NNPADOMDVIGVGGI ADOMDVIGVGGIDFE
. 18	B 7	GYTGANVRVAVFDTG	66		· —
19	B6	GANVRVAVFDTGLSE	67	F6	MDVIGVGGIDFEDNI
20	B5	VRVAVFDTGLSEKHP	68	F5	IGVGGIDFEDNIARF
21	B4	AVFDTGLSEKHPHFK	69	F4 F3	GGIDFEDNIARFSSR
22	В3	DTGLSEKHPHFKNVK	70		DFEDNIARFSSRGMT
23	B2	LSEKHPHFKNVKERT	71	F2	DNIARFSSRGMTTWE
24	B1	KHPHFKNVKERTNWT	72	F1	ARFSSRGMTTWELPG
25	C12	HFKNVKERTNWTNER	73	G12	SSRGMTTWELPGGYG
26	C11	NVKERTNWTNERTLD	74	G11 G10	GMTTWELPGGYGRMK
27	C10	ERTNWTNERTLDDGL	75		TWELPGGYGRMKPDI
28	C9	NWTNERTLDDGLGHG	76	G9	LPGGYGRMKPDIVTY
29	. C8	${ t NERTLDDGLGHGTFV}$	77		GYGRMKPDIVTYGAG
30	C7	TLDDGLGHGTFVAGV	78	G7 .	RMKPDIVTYGAGVRG
31	C6	DGLGHGTFVAGVIAS	7.9	G6	PDIVTYGAGVRGSGV
32	C5	GHGTFVAGVIASMRE	80	G5	VTYGAGVRGSGVKGG
33	C4	TFVAGVIASMRECQG	81	G4	GAGVRGSGVKGGCRA
34	· C3	AGVIASMRECQGFAP	82	G3	VRGSGVKGGCRALSG
35	C2	IASMRECQGFAPDAE	83	G2	SGVKGGCRALSGTSV
36	C1	MRECQGFAPDAELHI	84	G1	KGGCRALSGTSVASP
37	D12	CQGFAPDAELHIFRV	85	H12	CRALSGTSVASPVVA
38	D11	FAPDAELHIFRVFTN	86	H11	LSGTSVASPVVAGAV
39	D10	DAELHIFRVFTNNQV	87	H10	TSVASPVVAGAVTLL
40	D9	LHIFRVFTNNQVSYT	88	Н9	ASPVVAGAVTLLVST
41	D8	FRVFTNNQVSYTSWF	89	Н8	VVAGAVTLLVSTVQK
42	D7	FTNNQVSYTSWFLDA	90	H7	GAVTLLVSTVQKREL
43	D6	NQVSYTSWFLDAFNY	91	Н6	TLLVSTVQKRELVNP
44	D5	SYTSWFLDAFNYAIL	92	H5	VSTVQKRELVNPASM
45	D4	SWFLDAFNYAILKKI	93		VQKRELVNPASMKQA
46	D3	LDAFNYAILKKIDVL	94		RELVNPASMKQALIA
47	D2	FNYAILKKIDVLNLS	95	H2	VNPASMKQALIASAR
48	D1	AILKKIDVLNLSIGG	96	H1	ASMKQALIASARRLP
		•		• .	•

Human Protease and Use of Such Protease for Pharmaceutical Applications and for Reducing the Allergenicity of Non-Human Proteins David A. Estell Docket No. GC532-C1 Sheet 13 of 13

97	I12	IKDFHVYFRESRDAG
98	I11.	DAELHIFRVFTNNQV
99	- I10 '	KOALIASARRLPGVN
100	19	LIASARRLPGVNMFE
101	18	SARRLPGVNMFEQGH
102	17 17	RLPGVNMFEQGHGKL
103	Ī6	GVNMFEQGHGKLDLL
104	15	MFEQGHGKLDLLRAY
105	14	OGHGKLDLLRAYQIL
106	13	GKLDLLRAYQILNSY
107	I2	DLLRAYQILNSYKPQ
108	11	RAYQILNSYKPQASL
109	J12	OILNSYKPQASLSPS
110	J11	NSYKPQASLSPSYID
111	J10	KPQASLSPSYIDLTE
112	J9	ASLSPSYIDLTECPY
113	J8	SPSYIDLTECPYMWP
114	J7	YIDLTECPYMWPYCS
115	J6	LTECPYMWPYCSQPI
116	J5	CPYMWPYCSQPIYYG

FIG. 8B